 |
市場調査レポート
商品コード
1085808
無嗅覚症の世界市場：タイプ、治療、地域別 - 規模、シェア、見通し、機会分析（2022年～2028年）Anosmia Market, by Type, by Treatment (Therapies and Medications ), and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028 |
||||||
● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。 詳細はお問い合わせください。
価格
| 無嗅覚症の世界市場：タイプ、治療、地域別 - 規模、シェア、見通し、機会分析（2022年～2028年） |
|
出版日: 2022年05月10日
発行: Coherent Market Insights
ページ情報: 英文 140 Pages
納期: 2～3営業日
|
- 全表示
- 概要
- 目次
概要
無嗅覚症の症例の増加が、予測期間中の世界の無嗅覚症市場の成長を牽引すると期待される主要な要因です。また、市場企業は無嗅覚症治療のための新製品提供に向けた研究開発活動に注力しており、これによって予測期間中の市場成長が促進すると予測されます。
当レポートでは、世界の無嗅覚症市場について調査分析し、市場概要、市場力学、動向、競合情勢、企業プロファイルなど、体系的な情報を提供しています。
目次
第1章 調査目的・前提条件
第2章 市場概要
- レポート説明
- 市場の定義と範囲
- エグゼクティブサマリー
- 市場内訳：タイプ別
- 市場内訳：治療別
- 市場内訳：地域別
- コヒーレントオポチュニティマップ（COM）
第3章 市場力学・規制・動向分析
- 市場力学
- 促進要因
- 抑制要因
- 市場機会
- 主要なハイライト
- 製品パイプライン
- 規制シナリオ
- 製品の発売・承認
- PEST分析
- 合併・買収シナリオ
- 市場シェア分析
第4章 世界の無嗅覚症市場：コロナウイルス（COVID-19）パンデミックの影響
- COVID-19疫学
- 供給側分析・需要側分析
- 無嗅覚症に対するCOVID-19の影響
第5章 世界の無嗅覚症市場：タイプ別（2017年～2028年）
- イントロダクション
- 特発性無嗅覚症
- 先天性無嗅覚症
第6章 世界の無嗅覚症市場：治療別（2017年～2028年）
- イントロダクション
- 心理療法
- 投薬
第7章 世界の無嗅覚症市場：地域別（2017年～2028年）
- イントロダクション
- 北米
- ラテンアメリカ
- 欧州
- アジア太平洋
- 中東
- アフリカ
第8章 競合情勢
- ヒートマップ分析
- 企業プロファイル
- Mylan NV
- Pfizer Inc.
- Atom Pharma
- RANBAXY LABORATORIES LIMITED
- Alde Medi Impex
- GlaxoSmithkline plc
- Sandoz(Novasrtis AG)
- Inke SA
- Taj Pharmaceuticals Limited
- Sanofi
- アナリストの見解
第9章 セクション
目次
Product Code: CMI4334
Anosmia, the clinical term for the inability to smell. This disorder impair the ability to sense odors in the environment, as well as hinder the quality of life related to social interactions, eating, and feelings of well-being. It is a severe disability, affected genetically or accidentally, resulting in total/partial absence of olfactory guidance.
Market Dynamics
Rising anosmia cases is the major factor that is expected to drive growth of the global anosmia market during the forecast period. For instance, according to an article published by the National Institute on Deafness and Other Communication Disorders in February 2021, around 3% of U.S. populace have anosmia i.e.no sense of smell.
Market players are focusing on research and development activities for offering novel products for the treatment anosmia, which is expected to drive the market growth over the forecast period. For instance, in July 2020, Zydus Cadila received the U.S. Food & Drug Administration (U.S. FDA) approval for its supplemental abbreviated new drug application (SANDA) for Doxycycline Injection USP, 100 mg/vial, which seems to improve respiratory symptoms and anosmia
Key features of the study:
- This report provides in-depth analysis of the global anosmia market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
- It profiles leading players in the global anosmia market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
- Key companies covered as a part of this study include Mylan N.V., Pfizer Inc., Atom Pharma, RANBAXY LABORATORIES LIMITED, Alde Medi Impex, GlaxoSmithkline plc, Sandoz (Novasrtis AG), Inke S.A., Taj Pharmaceuticals Limited, and Sanofi, amongst others.
- Insights from this report would allow marketers and management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
- The global anosmia market report caters to various stakeholders in this industry including investors, suppliers, anosmia manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global anosmia market.
Detailed Segmentation
Global Anosmia Market, By Type
- Idiopathic Anosmia
- Congenital Anosmia
Global Anosmia Market, By Treatment
- Therapies
- Nasal Endoscopy
- Imaging
- Medications
- Decongestants
- Antihistamines
- Steroid Nasal Sprays
Global Anosmia Market, By Region
- North America
- By Country
- U.S.
- Canada
- By Type
- Idiopathic Anosmia
- Congenital Anosmia
- By Treatment
- Therapies
- Nasal Endoscopy
- Imaging
- Medications
- Decongestants
- Antihistamines
- Steroid Nasal Sprays
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Type
- Idiopathic Anosmia
- Congenital Anosmia
- By Treatment
- Therapies
- Nasal Endoscopy
- Imaging
- Medications
- Decongestants
- Antihistamines
- Steroid Nasal Sprays
- Europe
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- By Type
- Idiopathic Anosmia
- Congenital Anosmia
- By Treatment
- Therapies
- Nasal Endoscopy
- Imaging
- Medications
- Decongestants
- Antihistamines
- Steroid Nasal Sprays
- Asia Pacific
- By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- By Type
- Idiopathic Anosmia
- Congenital Anosmia
- By Treatment
- Therapies
- Nasal Endoscopy
- Imaging
- Medications
- Decongestants
- Antihistamines
- Steroid Nasal Sprays
- Middle East
- By Country:
- GCC
- Israel
- Rest of Middle East
- By Type
- Idiopathic Anosmia
- Congenital Anosmia
- By Treatment
- Therapies
- Nasal Endoscopy
- Imaging
- Medications
- Decongestants
- Antihistamines
- Steroid Nasal Sprays
- Africa
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- By Type
- Idiopathic Anosmia
- Congenital Anosmia
- By Treatment
- Therapies
- Nasal Endoscopy
- Imaging
- Medications
- Decongestants
- Antihistamines
- Steroid Nasal Sprays
- Company Profiles
- Mylan N.V.*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Pfizer Inc.
- Atom Pharma
- RANBAXY LABORATORIES LIMITED
- Alde Medi Impex
- GlaxoSmithkline plc
- Sandoz (Novasrtis AG)
- Inke S.A.
- Taj Pharmaceuticals Limited
- Sanofi
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Type
- Market Snippet, By Treatment
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Key Highlights
- Product Pipeline
- Regulatory Scenario
- Product launch/Approvals
- PEST Analysis
- Merger and Acquisition Scenario
- Market Share Analysis
4. Global Anosmia Market - Impact of Coronavirus (Covid-19) Pandemic
- COVID-19 Epidemiology
- Supply Side and Demand Side Analysis
- COVID-19 Impact on the Anosmia
5. Global Anosmia Market, By Type, 2017 - 2028 (US$ Million)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
- Idiopathic Anosmia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Congenital Anosmia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
6. Global Anosmia Market, By Treatment, 2017 - 2028 (US$ Million)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
- Therapies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Nasal Endoscopy
- Imaging
- Medications
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Decongestants
- Antihistamines
- Steroid Nasal Sprays
7. Global Anosmia Market, By Region, 2017 - 2028 (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, For Regions, 2017 - 2028
- Regional Trends
- North America
- Market Size and Forecast, By Type, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Treatment, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
- U.S.
- Canada
- Latin America
- Market Size and Forecast, By Type, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Treatment, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Market Size and Forecast, By Type, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Treatment, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Type, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Treatment, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Market Size and Forecast, By Type, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Treatment, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Type, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Treatment, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Country/Region, 2017 - 2028 (US$ Mn)
- South Africa
- Central Africa
- North Africa
8. Competitive Landscape
- Heat Map Analysis
- Company Profiles
- Mylan N.V.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Pfizer Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Atom Pharma
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- RANBAXY LABORATORIES LIMITED
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Alde Medi Impex
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- GlaxoSmithkline plc
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Sandoz (Novasrtis AG)
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Inke S.A.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Taj Pharmaceuticals Limited
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Sanofi
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Analyst Views
9. Section
- References
- Research Methodology
- About us and Sales Contact
